The latest medication for maculopathy’s cure is based on Aflibercept and is approved for use in Europe on 27 November 2012.
The medicine is administered with intravitreal injection and has the advantage to stop VEGF-A and PIGF. The blockage of PIGF (placental growth factor) is an important innovation for the cure of exudative maculopathy.
Moreover, using this drug, the intravitreal injection can be reduced. In USA, Aflibercept was approved even for the treatment of macular edema caused by retina’s central vein’s thrombosis.